Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2024 07:00 ET | Source: Oryzon Genomics, S.A.

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

FDA’s feedback supports the initiation of the Phase III trialAgitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indicationOryzon may use STAXI-2 Trait...
September 23, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

Strong improvement in State-Trait Anger Expression Inventory 2 (STAXI-2) Trait Anger, a measure of agitation and aggression, at Weeks 8–12 compared to previous top line data; nominal statistical...
September 11, 2024 12:07 ET | Source: Oryzon Genomics, S.A.

ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

MADRID and CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
September 09, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

Exploring the triple combination with venetoclax and azacitidineStudy sponsored by Oregon Health & Science University (OHSU) MADRID and CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) --...
September 03, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications

In Australia, Malaysia and Mexico MADRID and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company...
August 29, 2024 08:14 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in September

German Fall Conference 2024European College of Neuropsychopharmacology (ECNP) congress 2024Sachs Annual Biotech in Europe Forum 2024 MADRID, Spain and CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE...
July 31, 2024 08:32 ET | Source: Oryzon Genomics, S.A.

ORYZON reports financial results and corporate update for half-year ending June 30, 2024

Company granted an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial with vafidemstat in Borderline Personality Disorder (BPD)Final data from PORTICO, global...
July 08, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan

MADRID and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
June 28, 2024 09:28 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

All resolutions were approvedAdditional resolution to increase capital for up to 100 million euros approved42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 ...
June 26, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference

Selected for oral presentationConference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015,...